COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
BioNxt Solutions Inc. relocates R&D activities to Gen-Plus CRDO in Munich, Germany, enhancing capabilities and fostering collaborations in drug delivery systems, neurodegenerative therapeutics, and biomedical tech -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
BioNxt Solutions Inc. expands its intellectual property portfolio with new international patents for sublingual delivery technologies targeting autoimmune neurodegenerative diseases. The company aims to bring patient-friendly therapies to individuals affected by these diseases -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
BioNxt Solutions Inc. achieves key milestones in the development of BNT23001, a sublingual thin-film formulation of Cladribine for Multiple Sclerosis treatment, paving the way for clinical trials and regulatory submissions in 2025
